Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 14:13:965033.
doi: 10.3389/fgene.2022.965033. eCollection 2022.

Screening and validation of platelet activation-related lncRNAs as potential biomarkers for prognosis and immunotherapy in gastric cancer patients

Affiliations

Screening and validation of platelet activation-related lncRNAs as potential biomarkers for prognosis and immunotherapy in gastric cancer patients

Mingjie Yuan et al. Front Genet. .

Abstract

Background: Platelets (PLT) have a significant effect in promoting cancer progression and hematogenous metastasis. However, the effect of platelet activation-related lncRNAs (PLT-related lncRNAs) in gastric cancer (GC) is still poorly understood. In this study, we screened and validated PLT-related lncRNAs as potential biomarkers for prognosis and immunotherapy in GC patients. Methods: We obtained relevant datasets from the Cancer Genome Atlas (TCGA) and Gene Ontology (GO) Resource Database. Pearson correlation analysis was used to identify PLT-related lncRNAs. By using the univariate, least absolute shrinkage and selection operator (LASSO) Cox regression analyses, we constructed the PLT-related lncRNAs model. Kaplan-Meier survival analysis, univariate, multivariate Cox regression analysis, and nomogram were used to verify the model. The Gene Set Enrichment Analysis (GSEA), drug screening, tumor immune microenvironment analysis, epithelial-mesenchymal transition (EMT), and DNA methylation regulators correlation analysis were performed in the high- and low-risk groups. Patients were regrouped based on the risk model, and candidate compounds and immunotherapeutic responses aimed at GC subgroups were also identified. The expression of seven PLT-related lncRNAs was validated in clinical medical samples using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Results: In this study, a risk prediction model was established using seven PLT-related lncRNAs -(AL355574.1, LINC01697, AC002401.4, AC129507.1, AL513123.1, LINC01094, and AL356417.2), whose expression were validated in GC patients. Kaplan-Meier survival analysis, the receiver operating characteristic (ROC) curve analysis, univariate, multivariate Cox regression analysis verified the accuracy of the model. We screened multiple targeted drugs for the high-risk patients. Patients in the high-risk group had a poorer prognosis since low infiltration of immune killer cells, activation of immunosuppressive pathways, and poor response to immunotherapy. In addition, we revealed a close relationship between risk scores and EMT and DNA methylation regulators. The nomogram based on risk score suggested a good ability to predict prognosis and high clinical benefits. Conclusion: Our findings provide new insights into how PLT-related lncRNAs biomarkers affect prognosis and immunotherapy. Also, these lncRNAs may become potential biomarkers and therapeutic targets for GC patients.

Keywords: gastric cancer; immunotherapy; lncRNA; platelet; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The main process of this study.
FIGURE 2
FIGURE 2
Identification of PLT-related lncRNAs in patients with GC. (A) Univariate Cox regression analysis was used to extract the prognostic lncRNAs. (B) Heatmaps of 18 prognostic lncRNAs expression of patients (***p < 0.001 * *p < 0.01 *p < 0.05). (C) The LASSO coefficient profile of 18 PLT-related lncRNAs. (D) The LASSO coefficient distributions of OS-related lncRNAs and vertical dashed lines were plotted with the values selected for 10x cross-validation. (E) The results of qRT-PCR of PLT-related lncRNAs of 10 pairs GC patients.
FIGURE 3
FIGURE 3
Prognostic value of the risk model of the seven PLT-related lncRNAs in the testing set and training set. (AC) Distribution of PLT-related lncRNAs model presented based on a training set, testing set, and entire set risk scores. (DF) Survival time and survival status of low- and high-risk groups for the training set, testing set and entire set. (GI) Heat-maps of seven LncRNA expressions in the training set, testing set, and entire set. (JL) Kaplan-Meier survival curves of the OS of patients in the training set, testing set, and entire set. (MO) ROC curve of the training set, testing set, and entire set.
FIGURE 4
FIGURE 4
Correlation Analysis between risk score and Clinicopathological Features. (A,B) Univariate- and multivariate-Cox analyses of clinical characteristics and risk score with OS of the training set. (C,D) Univariate- and multivariate-Cox analyses of clinical characteristics and risk score with OS of the testing set. (E,F) Univariate- and multivariate-Cox analyses of clinical characteristics and risk score with OS of the entire set. (G) Kaplan-Meier survival curves of the OS of patients between the risk model and clinical characteristics (age, sex, TNM stage, grade, and survival status). (H) Heat-map of correlation between high- and low-risk and patient clinical characteristics (***p < 0.001 * *p < 0.01 *p < 0.05).
FIGURE 5
FIGURE 5
Pathway Enrichment Analysis. (A) GSEA analysis of the high- and low-risk groups.
FIGURE 6
FIGURE 6
Potential role of the risk model in the TME and immunotherapy. (A) The content of 22 immune cells between the high- and low-risk groups. (B) TME Estimate-Scores, Immunity-Scores, and Stromal-Scores measured between high- and low-risk groups. (C,D) Differences in microsatellite instability (MSI) between patients in the high- and low-risk groups. (E) Differences in immunotherapy scores between high- and low-risk groups.
FIGURE 7
FIGURE 7
Correlation analysis of PLT-related lncRNAs with methylation and EMT. (A) Differences of 5mC Regulator expression between patients in the high- and low-risk groups. (B) Differences of EMT-related gene expression levels among high- and low-risk groups.
FIGURE 8
FIGURE 8
Construction and Assessment of the Novel Nomogram. (A) The nomogram that predicted 1 -, 2 -, and 3-year survival probabilities. (BD) The calibration curve for 1 -, 2 -, and 3-year OS.

References

    1. Afshar-Kharghan V. (2017). The role of the complement system in cancer. J. Clin. Invest. 127 (3), 780–789. 10.1172/JCI90962 - DOI - PMC - PubMed
    1. Bao Y., Wang L., Shi L., Yun F., Liu X., Chen Y., et al. (2019). Transcriptome profiling revealed multiple genes and ECM-receptor interaction pathways that may be associated with breast cancer. Cell. Mol. Biol. Lett. 24, 38. 10.1186/s11658-019-0162-0 - DOI - PMC - PubMed
    1. Cao M., Li H., Sun D., Chen W. (2020). Cancer burden of major cancers in China: A need for sustainable actions. Cancer Commun. 40 (5), 205–210. 10.1002/cac2.12025 - DOI - PMC - PubMed
    1. Chandra Gupta S., Nandan Tripathi Y. (2017). Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. Int. J. Cancer 140 (9), 1955–1967. 10.1002/ijc.30546 - DOI - PubMed
    1. Chen B., Khodadoust M. S., Liu C. L., Newman A. M., Alizadeh A. A. (2018). Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol. Biol. 1711, 243–259. 10.1007/978-1-4939-7493-1_12 - DOI - PMC - PubMed